Nicholas A.j. Botwood - 04 Feb 2026 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Head of R&D, CMO
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
04 Feb 2026
Net transactions value
+$2,956,221
Form type
4
Filing time
06 Feb 2026, 16:50:19 UTC
Previous filing
19 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Botwood Nicholas A.J. Head of R&D, CMO 730 THIRD AVENUE, FLOOR 9, NEW YORK /s/ Michael A. Metzger, Attorney-in-Fact 06 Feb 2026 0002066784

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Award $0 +24,000 +68% $0.000000 59,165 04 Feb 2026 Direct F1
transaction SNDX Common Stock Award $0 +36,000 +61% $0.000000 95,165 04 Feb 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $2,956,221 +144,700 $20.43 144,700 04 Feb 2026 Common Stock 144,700 $20.43 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested.
F2 Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company.
F3 1/48th of the shares subject to the option shall vest monthly over a four-year period.